Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in adults with immune thrombocytopenia
NL-OMON60512Phase 2Completed
- Sponsor
- Principia Biopharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Principia Biopharma. Primary endpoints: Incidence of treatment-emergent adverse events, Consecutive increased platelet counts and 1 more. Started Sep 2019; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON60512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60512.